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Background: The effectiveness of antibiotics in
chronic obstructive pulmonary disease (COPD)
exacerbations is still a matter of debate, especially in
outpatients with an intermediate probability of bacterial
infection.
Methods: In this study, 35 COPD outpatients
diagnosed by their chest physician with moderately
severe COPD exacerbation, but without pneumonia,
were randomised in a double blind, placebo-controlled
study. Patients had one or two of the following
characteristics: a positive Gram’s stain of the sputum, 2
or more exacerbations in the previous year, a decrease
in lung function of >200 mL and >12%. Patients
received amoxicillin clavulanic acid (500/125 mg three
times daily) or placebo for 7 days, always combined
with a course of prednisolone (30 mg/day) for 7 days.
Primary outcome was duration of the exacerbation.
Additionally, we measured severity of the exacerbation,
health-related quality of life, sputum parameters,
number of relapses within 28 days and the number of
re-exacerbations within 4 months after the study.
Results: There was no difference observed in time to
resolution of the exacerbation between the two groups
(HR=1.12; (95% CI 0.5 to 2.3; p=0.77)), nor in any
other treatment parameter.
Conclusions: We detected no evidence for the
effectiveness of addition of antibiotics to prednisolone
for COPD exacerbations of moderate severity and with
intermediate probability of bacterial infection in this
underpowered study. More placebo-controlled studies
are needed to properly define subgroups of COPD
outpatients in which antibiotics are of additional value.
Trials registration number: clinical trial registered
with http://www.trialregister.nl/(NTR351).
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is characterised by acute exacerbations
(AECOPD) that are associated with substantial
morbidity and mortality.1–3 Management of
AECOPD includes oral corticosteroids often
combined with broad spectrum antibiotics to
treat a presumed bacterial infection.4 Some
antibiotics, especially the macrolides, are also
sometimes provided prophylactically for longer
term use due to their anti-inflammatory, immu-
nomodulatory or antiviral effects.5 A short
course of broad spectrum antibiotics during
AECOPD is, however, mainly used for their anti-
bacterial effect. Their use remains controversial
due to several reasons. First only approximately
one-third of AECOPD are due to bacterial
infections.6 Second, given the existence of bac-
terial infections, the treatment is empirical
since culture and resistance results usually take
1 week to become available. Third, growing
resistance against antibacterial agents is an add-
itional reason to be reluctant to give a prescrip-
tion of antibiotics.7 8 Finally and perhaps most
importantly, there is no definitive evidence that
antibiotics offer benefits in outpatients with
mild-to-moderate AECOPD.9 10
The latest international guidelines recom-
mend antibiotics to patients with AECOPD
who have three cardinal symptoms (increase in
dyspnoea, sputum volume and sputum puru-
lence); patients who have two of the cardinal
symptoms, if increased purulence of sputum is
one of the two symptoms; or to patients who
require mechanical ventilation (invasive or
non-invasive).11 These criteria originated from
the study by Anthonisen et al12 which showed
only a marginal benefit from antibiotics in a
subgroup of patients. They divided AECOPD
into three categories and concluded that in
case of the presence of all three of the above
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mentioned criteria (type I) the cause of the AECOPD is
probably bacterial and is more likely to have a favourable
outcome with antibiotics.12
Unfortunately, most placebo-controlled antibiotics trials,
on which these guidelines are based, have important limita-
tions and are difficult to compare because of different defi-
nitions of COPD and AECOPD, and different end points
that have been used.13 14 Furthermore, these trials were
conducted several decades ago, before systemic steroids
were widely introduced for the treatment of AECOPD.15–18
Even in the recently published study by Llor et al,19 in
which a beneficial effect with amoxicillin/clavulanic acid
compared to placebo was observed, only 17% of the
patients were treated with systemic steroids.20 Furthermore,
as stated in the Cochrane Review of Vollenweider et al,
when the analyses on the effects of antibiotics are restricted
to currently used drugs, antibiotics do not significantly
reduce treatment failure in outpatient AECOPDs.
Van der Valk et al21 reported that an Anthonisen type I
AECOPD did not predict a bacterial origin of an outpati-
ent’s AECOPD and that sputum purulence was poorly
associated with bacterial infection. This study did, however,
found that the combination of a positive Gram’s stain of
sputum, a clinically relevant lung function decrease and
>two AECOPDs in the previous year were 67% predictive
for a bacterial origin of the AECOPD and therefore, postu-
lated to warrant antibiotic treatment. The absence of all
three characteristics gave a negative predictive value of
100% for a non-bacterial origin, suggesting to abstain from
administering the antibiotics.21 This leaves patients with
one or two of these characteristics. Therefore, in the
current double-blind, randomised, placebo-controlled
study, we evaluated the effect of an antibiotic on the dur-
ation and severity of AECOPDs in outpatients with one or
two of the three mentioned characteristics.
METHODS
Patients
Patients with COPD were recruited from May 2005 till
January 2007 from the outpatient pulmonary clinic of
Medisch Spectrum Twente, Enschede, The Netherlands.
Patients had to meet the following criteria: (1) a diagno-
sis of COPD according to the GOLD-criteria; (2) current
or ex-smoker; (3) age 40–80 years; (4) presenting at the
outpatient clinic with an AECOPD, defined as an acute
negative change in dyspnoea and/or sputum volume
and/or colour of sputum (yellowish or greenish) and/
or cough, which warrants additional treatment with
prednisolone with or without antibiotics by a physician;
(5) no requirement of hospitalisation (6) no pneumonia
based on chest X-ray;22 (7) ability to produce a spontan-
eous sputum sample; (8) presenting with one or two of
the clinical characteristics: a positive Gram’s stain of
sputum, a clinically relevant lung function decrease
(decrease in FEV1 of >200 mL and >12% from baseline),
or >2 AECOPDs in the previous year;21 (9) no AECOPD
or use of antibiotics or prednisolone 4 weeks prior to
enrolment, except for low-dose prednisolone (≤5 mg) as
maintenance therapy; (10) no disease that influences
bronchial symptoms or lung function; (11) no mainten-
ance therapy with antibiotics; (12) no known hypersensi-
tivity to amoxicillin/ clavulanic acid; (13) no medical
condition with low survival or serious psychiatric morbid-
ity; (14) no uncontrolled diabetes mellitus; (15) no
need for domiciliary oxygen therapy; and (16) no par-
ticipation in another clinical trial.
The hospital’s medical ethics committee approved the
study. All patients provided written informed consent.
Study design
This study was a randomised, double blind, placebo-
controlled study. Eligible patients were randomly assigned
in a one-to-one ratio to either the intervention or control
group based on a computer generated randomisation list.
The hospital pharmacy provided both amoxicillin/clavu-
lanic acid and placebo in identical containers with identi-
cal capsules. Based on the randomisation list, the hospital
pharmacy sequentially numbered the containers with
both amoxicillin/clavulanic acid and placebo. This list
was kept in a safe at the hospital pharmacy throughout
the course of the study. Patients received these numbered
containers in sequence of randomisation, which was
recorded on a medication distribution list.
Patients in both groups received oral prednisolone,
30 mg/day for 7 days. Patients in the intervention group
additionally received oral amoxicillin/clavulanic acid
(Augmentin) 500/125 mg three times daily for 7 days,
while control patients received a matching placebo. The
choice for this amoxicillin/clavulanic acid is based on
the negligible prevalence of organisms resistance in our
region (less than 5%). All patients continued their pre-
scribed inhaled regimen. Patients were followed for
28 days for the primary outcome and for 4 months to
detect new AECOPDs.
Outcome measures
The primary outcome was the duration of the AECOPD.
Start of the AECOPD was defined as the day the patient
presented with an AECOPD at the outpatient clinic. The
end day of the AECOPD was based on a symptom diary,
which patients completed daily.23 In this diary, patients
reported whether their major symptoms and minor symp-
toms, according to Anthonisen et al12 (table 1), were
beyond normal. At inclusion all patients received a ‘what is
normal’ card on which their individual levels of major
symptoms in stable health state were recorded. This card
was used as a reference for the diary. When patients
experienced no increase in severity of any symptoms listed
in the diary, they could tick ‘no change in symptoms’. In
all other cases, they had to report on all the symptoms in
the diary - whether the level of each symptom was normal,
whether there was a small increase or an evident increase
in severity compared to their stable state.
The last day of the AECOPD was defined as the first
day of: (1) three consecutive days when the patient had
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returned to his normal health state; or (2) seven con-
secutive days in which patients only reported a minor
increase in symptoms compared to baseline, without
fever or changed sputum colour.
Secondary outcome measures were the severity of the
AECOPD, number of relapses of AECOPDs within
28 days, number of AECOPDs within 4 months, lung
function parameters, sputum parameters and HRQoL.
Severity of the AECOPD was based on the symptom
scores in the diary and was calculated as predefined in
the protocol. On each day of the AECOPD, a severity
score was calculated (table 1). Adding the symptom
scores resulted in a daily score ranging from 0 to 11
points. A mean severity score per AECOPD day was cal-
culated by dividing the sum scores of each AECOPD day
by the number of days the AECOPD lasted.23
A relapse was defined as an AECOPD that resolved fol-
lowing the blinded treatment but re-occurred within
28 days of the treated AECOPD. The number of
AECOPDs within 4 months was estimated by counting
the number of courses of prednisolone and antibiotics
prescribed for lung-associated illness, based on data from
pharmacy records. In our region this provides a very
accurate coverage of consumption. Pharmacy data were
similarly used to determine the number of AECOPDs in
the year prior to the start of the study.
At the start of the study and after 28 days, lung func-
tion was measured. Spontaneous sputum samples were
collected and sputum colour was determined according
to the Stockley protocol nine-point colour chart
(BronkoTest, Heredilab Inc, Salt Lake City, Utah,
USA).24 Sputum with a colour value ≤2 was defined as
‘mucoid’ and sputum colour ≥3 was defined as ‘puru-
lent’. Subsequently, a Gram’s stain and a semiquantita-
tive culture were made. Infection was defined by the
presence of potentially pathogenic micro-organisms
(PPM) in pure culture or by the presence of one or
more PPM in excess (one log or more) to background
microbiological flora in sputum.21 25 Bacterial colonisa-
tion was defined as the presence of PPM in culture in
equal amount or less compared to background micro-
biological flora in sputum.
The level of PCT was measured in blood samples that
were derived at the start. PCT levels were assessed with an
automated sandwich immunoassay using a time-resolved
amplified cryptate emission technology (TRACE; Kryptor
PCT; Brahms AG; Hennigsdorf, Germany).The PCT
assays has a detection limit of 0.02 ng/mL and a
functional assay sensitivity of 0.06 ng/mL. PCT levels
were also divided based on the cut-off levels determined
by Stolz et al26 that were set at >0.1 µg/L, between
0.1–0.25 µg/L and >0.25 µg/L.
HRQoL was measured by means of the Chronic
Respiratory Questionnaire (CRQ).27 Health status was mea-
sured with the Clinical COPD Questionnaire (CCQ).28 29
Statistical analysis
With an expected mean duration of an exacerbation of
approximately 15 days, a difference of 3 days in the dur-
ation of AECOPD between the treatment groups was
defined prior to the study as clinically relevant. With a
SD of 4 days, power of 80%, and α of 5%, 58 patients
were required to detect this difference.
The relation between treatment and the duration of the
AECOPD was analysed by Cox-regression analysis. To iden-
tify continuous variables that were different between treat-
ment group, t tests or Mann-Whitney U test for the
normally and not normally distributed variables were per-
formed. Between-group comparisons of categorical vari-
ables were performed by χ2 tests or Fisher’s exact tests, as
appropriate. The a priori list of potential confounding
variables is displayed in table 2. Only variables different by
treatment group (p≤0.20) were tested for an association
with duration of the AECOPD. Variables associated with
duration of the AECOPD with p≤0.20 were considered as
potential confounders in the relation between treatment
and duration of the AECOPD, and were entered into the
multivariate Cox-regression analysis. Time to resolution
was displayed as a Kaplan-Meier graph.
RESULTS
Of 63 potentially eligible patients with an AECOPD, 35
patients were randomised; 18 received amoxicillin/
Table 1 Scoring of COPD AECOPD symptoms
Normal Small increase Evident increase/change
Major symptoms
Dyspnoea 0 1 2
Sputum production 0 1 2
Sputum colour 0 2*
Minor symptoms
Cough 0 0.5 1
Wheeze 0 0.5 1
Running nose 0 0.5 1
Sore throat 0 0.5 1
Fever 0 1†
*Sputum colour: normal=0; different from normal=2.
†Fever (>38.5°C): no=0; yes=1.
AECOPD, acute exacerbations in COPD; COPD, chronic obstructive pulmonary disease.
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clavulanic acid and 17 placebo (figure 1). All patients
completed the treatment and follow-up. Baseline
characteristics are displayed in table 2. At baseline, FEV1
(in litres and as % predicted), sputum culture, colour
and purulence showed to be potential confounders since
these were associated to treatment with p<0.20.
Therefore, these variables were tested for association with
the duration of treatment (also p<0.20). Since this was
not the case for any variable, no adjustment of treatment
effect on the duration of the AECOPD was necessary.
In 15 patients (83%) in the intervention group, the
AECOPD resolved within 28 days compared to 14
patients (82%) that received placebo (see table 3). Since
not all of the AECOPDs resolved within 28 days, we were
not able to calculate the mean duration of the
AECOPD. Therefore, we calculated the median time till
resolution which was 7 days (95% CI 2.8 to 11.2) in the
amoxicillin group compared to 10 days (95% CI 3.3 to
16.7) in the placebo group (p=0.75).
The crude HR of time to resolution of the AECOPD
in patients in the intervention group was 1.12 (95% CI






Gender (number of men (%)) 9 (50) 12 (71) 0.21
Smoking status (number (%)) 0.42
Ex-smokers 14 (78) 11 (65)
Current smokers 4 (22) 6 (35)
Age (median (range)) 68 (54–74) 65 (47–76) 0.38
Lung function postbronchodilation at inclusion (SD)
FEV1 in litres 1.24 (0.44) 1.53 (0.54) 0.06
FEV1% predicted 44.7 (15.4) 52.2 (15.1) 0.16
FEV1/VC % 38.3 (13.0) 42.9 (11.2) 0.27
Positive Gram’s stain (number (%)) 15 (83) 15 (88) 1.00
Sputum culture at inclusion (Number (%)) 0.18
No colonisation nor infection 3 (17) 5 (29)
Colonisation 2 (11) 5 (29)
Infection 13 (72) 7 (41)
AECOPDs in the previous year (number (%)) 0.63
<2 AECOPDs 7 (39) 8 (47)
≥2 AECOPDs 11 (61) 9 (53)
Lung function decline of ≥200 mL and ≥12% at start of AECOPD
compared to baseline* (number (%))
2 (11) 2 (12) 1.00
Sputum colour score† (SD) 4.4 (1.2) 3.4 (1.1) 0.02
Purulent sputum (number (%)) 17 (94) 13 (77) 0.17
Type of AECOPD according to Anthonisen (number (%)) 0.44
Type I (3 major symptoms) 15 (83) 12 (71)
Type II (2 major symptoms) 3 (17) 5 (29)
Type III (1 major+1 minor symptom) 0 0
Procalcitonin level (µg/L) (median (range)) 0.06 (0.03–0.22) 0.06 (0.04–0.11) 0.42
Procalcitonin cut-off level (number (%)) 1.00
<0.1 µg/L 17 (94) 16 (94)
0.1–0.25 µg/L 1 (6) 1 (6)
>0.25 µg/L 0 0
To identify variables that were different by treatment group, t tests in case of normally distributed variables were performed. For not normally
distributed variables this was performed by Mann-Whitney U test. Between-group comparisons of categorical variables were performed by χ2
tests or Fisher’s Exact tests as appropriate.
*Baseline lung function was an earlier in stable state performed lung function measurement.
†Score according to the Stockley protocol with the nine-point colour chart (Bronko Test, Heredilab Inc, Salt Lake City, Utah, USA).
AECOPD, acute exacerbations chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; VC, vital capacity.
Figure 1 CONSORT flow chart diagram.
4 Brusse-Keizer M, VanderValk P, Hendrix R, et al. BMJ Open Resp Res 2014;1:e000052. doi:10.1136/bmjresp-2014-000052
Open Access
0.54 to 2.32; p=0.77) compared to the placebo group
(figure 2).
Table 3 shows that there were no differences in any of
the other treatment effects between the groups.
Additional analyses
Seventy-nine per cent and 82% of the patients in the
intervention and placebo group, respectively, thought
they had received placebo.
At inclusion the treating physician of each patient was
asked what would have been prescribed had the patient
not participated in the trial. In 34% of patients, the
physician would have treated the patient with prednisol-
one only and in 66%, with both prednisolone and
antibiotics.
DISCUSSION
This randomised, placebo-controlled trial demonstrated
no difference in time taken for the resolution of
AECOPDs in outpatients treated with either amoxicillin/
clavulanic acid or placebo in addition to prednisolone.
Also no difference in severity, number of relapses,
number of AECOPDs 4 months after the study or
HRQoL was observed. These conclusions apply only to
patients with one or two of the following characteristics:






Resolution of AECOPD within 28 days (number (%)) 15 (83) 14 (82) 1.00
Daily AECOPD severity score (median (range)) 5.7 (4.3–7.8) 5.4 (2.4–8.4) 0.70
Number of AECOPD days with a severity score >6
(median (range))
3 (0–25) 3 (0–24) 0.68
Relapse within 28 days (Number (%)) 2 (11) 1 (6) 1.0
Number of AECOPDs within 4 months after end of study
(number (%))
0.66
0 7 (39) 10 (59)
1 6 (33) 4 (24)
2 4 (22) 3 (18)
3 1 (16) 0 (0)
Change in CCQ scores from inclusion to day 28 (mean (SD))
Total −2.3 (2.7) −2.3 (2.7) 0.88
Mental state −0.6 (1.5) −0.3 (1.3) 0.55
Functional state −0.6 (1.0) −0.8 (1.0) 0.72
Symptom −1.2 (1.4) −1.2 (1.4) 0.92
Change in CRQ scores from inclusion to day 28 (mean (SD))
Dyspnoea 0.5 (1.3) 0.5 (1.6) 0.91
Fatigue 1.2 (1.2) 0.4 (1.3) 0.07
Emotional function 0.1 (0.9) 0.6 (1.2) 0.23
Mastery 0.3 (1.4) 0.4 (1.4) 0.94
Change in lung function postbronchodilation from inclusion to day 28 (mean (SD))
FEV1 in litres 0.02 (0.21) 0.07 (0.27) 0.51
FEV1% predicted 1.6 (8.8) 2.4 (8.9) 0.80
Change in sputum colour from inclusion to day 28 (mean (SD))* −0.46 (1.1) 0.2 (2.7) 0.39
Change in sputum purulence from inclusion to day 28
(number (%))
0.57
Mucoid to mucoid 1 (6) 2 (12)
Mucoid to purulent 0 2 (12)
Purulent to purulent 11 (61) 8 (47)
Purulent to mucoid 6 (33) 5 (29)
Procalcitonin level (µg/L) (median (range)) 0.06 (0.03–0.26) 0.05 (0.03–0.24) 0.28
Procalcitonin cut-off level (number (%)) 0.48
<0.1 µg/L 15 (83) 16 (94)
0.1–0.25 µg/L 2 (11) 1 (6)
>0.25 µg/L 1 (6) 0
To identify treatment effects that differed between the treatment groups, t tests in case of normally distributed variables were performed. For
not normally distributed variables this was performed by Mann-Whitney U test. Between-group comparisons of categorical variables were
performed by χ2 tests or Fisher’s Exact tests as appropriate.
*Score according to the Stockley protocol with the nine-point colour chart (BronkoTest, Heredilab Inc, Salt Lake City, Utah, USA).
AECOPD, acute Exacerbation in COPD; CCQ, Clinical COPD Questionnaire; CRQ, Chronic Respiratory Questionnaire.
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a positive Gram’s stain of sputum, a clinically relevant
lung function decrease, and two or more AECOPDs in
the previous year.
As detailed in the introduction, there is a paucity of
good placebo-controlled studies on the effect of antibio-
tics in AECOPDs in addition to the treatment with sys-
temic steroids.
Though there are large differences in prescription
routines between and within countries, many physicians
tend to err on the ‘safe’ side and therefore, also give
antibiotics. In the current trial too we observed that 66%
of the patients would have been treated with antibiotics
by their physician. This routine has implications for
costs, adverse effects and for the surge in antibiotic
resistance12 especially. Therefore, evidence needs to be
established also in the group with less severe AECOPDs.
Anthonisen et al performed post hoc analyses stating
that type I AECOPDs were likely to be bacterial and
have a more favourable outcome with antibiotics. They
stated that antibiotics confer no benefit in type III
AECOPDs and that treatment of type II AECOPDs with
antibiotics probably could be justified in case of anti-
biotic tolerance.24 A remarkable finding in our study was
that a bacterial infection was present in only 15 (56%)
of the 27 type I AECOPDS. Additionally, although 15
(83%) and 12 (71%) of the AECOPDs in the amoxicil-
lin/clavulanic acid and the placebo group, respectively,
were type I Anthonisen, no effect from antibiotics was
observed. These results give food for thought about the
effectiveness of antibiotics in this type of AECOPD. The
main difference between the study by Anthonisen and
ours is the concomitant use of prednisolone, which is
the standard recommendation nowadays. In the
Anthonisen study only 42% received systemic steroids.
The authors state that the success rate with antibiotics
was favourable in both steroid and non-steroid users, but
no data are provided. We believe that room for improve-
ment by antibiotics will generally be less in patients
treated with prednisolone, certainly in those with less
severe AECOPDs.
Besides the type of Anthonisen AECOPD, we also mea-
sured PCT since this has been shown to be a marker of
systemic bacterial infection.30In the study of Stolz et al,31
PCT was also elevated at hospitalisation for AECOPD.
One study suggested that PCT can be used as criterion
for decisions on whether to start antibiotics.26 However,
this could not be reproduced in another study.32 In
our study, in which instead of hospitalised AECOPD
patients, outpatients with an AECOPD were included,
we observed that 20 (57%) of our patients with an
AECOPD experienced a bacterial infection but that only
2 (6%) had a PCT level between 0.1 and 0.25 µg/L,
which indicates possible bacterial infection. None of the
patients had a PCT level >0.25 µg/L which suggests the
presence of bacterial infection. Therefore, our results
suggest that PCT is not an informative biomarker as a
criterion for decisions on whether to start antibiotics in
outpatient AECOPD with an intermediate probability of
infection.
In this study we observed that even though 57% of the
patients experienced a bacterial infection, antibiotics had
no added value in these patients. Although this suggests
refraining from administering antibiotics in outpatient
AECOPDs, this inference should not be generalised from
our data to all outpatients, since our patients were
selected for not having a high probability of bacterial
infection.21 We believe, however, that our results merit a
supplementary randomised, placebo-controlled trial in
patients with a high probability of an AECOPD of bacter-
ial origin.
In our additional analyses, we observed that the large
majority of patients on antibiotics thought they had
received placebo (79%) which was very similar to the
percentage in the group that really received placebo
(82%). This suggests that the patients were not aware of
any effect that could be caused by the antibiotics.
An important limitation of this study is the number of
patients included. Based on our power calculation, we
needed to include 58 patients to be able to detect a differ-
ence of 3 days in AECOPD duration between the treat-
ment groups. We were able to include only 35 patients
within the time allotted. The majority of patients were not
eligible due to: their participation in the COPE II
study,23an AECOPD or use of antibiotics or prednisolone
4 weeks prior to enrolment or their inability to produce
a spontaneous sputum sample. However, with the
observed HR of 1.12 and the median time to resolution of
10 days in the control group, the required sample size
Figure 2 Kaplan-Meier graph showing time to resolution for
both treatment groups.
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would be 2450 patients. With this enormous number of
patients we might have found a significant difference,
but we suggest that this difference would not be
clinically relevant. We, therefore, feel that the lack of effect
of antibiotics is not completely based on not including 58
patients. We should, however, realise that due to the
smaller number of patients included, the probability of a
type II error – not rejecting the null hypothesis in case of a
difference between arms – in this study will be higher than
the 20% based on the power of 80%.
CONCLUSION
In conclusion, this underpowered, randomised, placebo-
controlled study observed no added value of treatment
with antibiotics in outpatients with moderate to severe
AECOPDs and intermediate probability of infection.
Instead of more equivalence trials comparing two anti-
biotics, we need more placebo-controlled studies to
determine whether we can properly define subgroups of
COPD outpatients in which antibiotics indeed are of
additional value and in whom there is no use at all.
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